Even though the clinical benefit observed in this subset of patients is lower than observed in patients with LKB1 wild-type NSCLC, first-line chemo-immunotherapy remains the standard-of-care, first-line therapy for the majority of advanced LKB1-inactive NSCLC patients. Here, STK11 is linked to non-small cell lung carcinoma.